Introduction
It has been reported that thyroid carcinomas, the most frequently reported endocrine neoplasia, account for only 3%-4% in all human tumors, but the incidence of thyroid cancer is steadily increasing and has the highest increase in incidence within the past two decades. 1 Currently, the use of neck ultrasonography is widely used in the diagnosis of thyroid cancer and brings light to the detection of many small early-stage tumors. 2 However, the incidence of detection of large tumors and advanced stage tumor patients have also increased in these years. 3, 4 Thyroid cancer can be categorized into submit your manuscript | www.dovepress.com
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shou et al four histotypes: follicular thyroid carcinoma (FTC), papillary thyroid carcinoma (PTC), anaplastic thyroid carcinoma, and medullary thyroid carcinoma (MTC). PTC, the most common type of thyroid cancer, represents 80% of patients, followed by FTC (10%). 5, 6 PTC derives from the follicular cells of the thyroid, and it has a distinctive papillary architecture. In addition, the nuclear membrane of cells in PTC has several distinctive alternations, such as grooves, pseudoinclusions, and optical clearing. In contrast to the papillary carcinomas, in which the change of nuclear membrane alternations is vital, the diagnosis of FTC depends on whether the thyroid tumor has invaded through the surrounding vessels. MTC has a rare incidence accounting for ~3%, which derives from parafollicular C cells. 7 Compared with FTC and PTC -well differentiated cancer -MTC has a more aggressive clinical characteristic. 8 MTC often occurs in a form of inherited cancer, which is known as multiple endocrine neoplasia type 2. 9 In recent decades, although many genetic studies for thyroid cancer have been performed, no specific biomarkers for the large number of sporadic thyroid cancers have been found. [10] [11] [12] The Ras-associated domain family 1 (RASSF1) family of proteins, representing one type of Ras effectors, can inhibit the development of cancer. RASSF1A, one of the seven isoforms of the RASSF1 family and located on 3p21, is the most common epigenetically inactivated tumor suppressor genes via promoter methylation in human cancers. 13, 14 It can bind Ras protein in a guanosine triphosphate-dependent manner to mediate the cell apoptotic, which has a similar function with Nore1 in mouse.
14 In many solid tumors, RASSF1A, as a component of crucial cell signal pathways, plays an important role in the Ras/PI3K/AKT, Ras/RAF/MEK/ERK, and Hippo pathways, and the inactivation of RASSF1A can result in the alternations of clinical characteristic in tumors. 15, 16 It has been reported that the CpG methylation of RASSF1A promoter can lead to the loss-of-expression of RASSF1A.
14 Previous studies have found that the RASSF1A promoter methylation can increase the risk of lung cancer, breast cancer, prostate cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, and gastric cancer. [17] [18] [19] [20] [21] [22] [23] [24] Furthermore, these results indicated that the RASSF1A promoter methylation may be a significant prognostic factor for many human cancers. Despite a number of studies performed on thyroid cancer patients, the relationship of RASSF1A promoter methylation with thyroid cancer risk and pathogenesis remains controversial. To clarify these controversial results, a meta-analysis was performed.
Methods
Publication search
Relevant literature was retrieved from PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases up until September 2016, without language restrictions. The following keywords were applied: "RASSF1 protein, human (Supplementary Concept)," "Thyroid Neoplasms (Mesh)," "Methylation (Mesh)," "RASSF1A," "thyroid cancer," and "hypermethylation" to search eligible studies. Review articles and the references from relevant primary studies were manually searched for identifying additional potential studies.
inclusion and exclusion criteria
The inclusion criteria were as follows: 1) studies primarily evaluating the frequency of RASSF1A promoter methylation in thyroid cancer with control group, 2) studies that have a casecontrol design, 3) studies that had sufficient data of frequency, and 4) patients who had been accurately diagnosed according to the diagnostic criteria. Studies were removed if they met one of the items: 1) reviews, meta-analysis, or animal studies; 2) duplicate data; and 3) study performed in the cell lines.
Data extraction
The following data were extracted from the eligible studies: year of publication, country, ethnicity, frequency of RASSF1A promoter methylation, cancer type, method of methylation detection, and sample type. The information was reviewed by two investigators. If the two investigators had divergence, the disagreement was resolved by consulting with the other authors.
Quality assessment
To ensure the high quality of included literatures, the Newcastle-Ottawa scale (NOS) table was applied to assess the methodological quality of observational studies. The NOS is commonly used in the quality assessment of nonrandomized studies, such as case-control and cohort studies. The scores of quality assessment range from 0 to 9. If the study got a score 5 it was excluded.
Trial sequential analysis
In a cumulative meta-analysis, false-positive and false-negative results may arise, which result from the repeated testing and the adding of other studies. Therefore, it was crucial to lower the risk of type I error and type II error in the repeated statistics. In addition, interim analysis was performed to
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rassF1a methylation increases thyroid cancer risk estimate the required sample size according to the data in the common trials and to avoid wasting of the sample. In this present meta-analysis, the trial sequential analysis was performed to estimate the required information size (RIS) and observe whether the result was conclusive through controlling the risk of type I error and type II error. TSA 0.9 software (www.ctu.dk/tsa) was applied to conduct these analyses by combining the RIS with trial sequential monitoring boundaries. The trial sequential analysis was conducted at the level of 5% risk of type I error and 80% power of statistical test (5% risk of type II error). Moreover, adjusted information size was calculated with a relative risk reduction (−50%) according to the incidence of control and case groups.
statistical analysis
The frequency of RASSF1A promoter methylation in case and control groups was collected to calculate the pooled odds ratios (ORs) and 95% confidence interval (CI), 25 evaluating the strength of association of RASSF1A promoter methylation with thyroid cancer risk or thyroid cancer clinical characteristics. Heterogeneity among studies was measured using Cochran's Q-test and Higgin's I 2 . 26, 27 If heterogeneity existed in studies (P0.05, I
2 50%), random-effects model was applied, otherwise, fixed-effects model was used (P0.05, I 2 50%). 28, 29 In addition, subgroup analysis based on ethnicity and sample type were conducted to detect the source of heterogeneity and lower the between-study heterogeneity. Begg's test and Egger' test were used to check for the publication bias. When the P-value was 0.05, publication bias was considered as significant. The aggregated sensitivity and specificity were observed by conducting the sensitivity analysis. All meta-analyses were performed using Stata software 12.0 (Stata Corporation, College Station, TX, USA).
Results
characteristics of studies
Through searching PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases, 25 publications were initially retrieved. Eight duplicate articles were removed. After reading titles and abstracts, four articles were excluded due to uncorrelated contents. Furthermore, full-text was read to eliminate irrelevant literatures, and two articles were eliminated because they had no sufficient data of RASSF1A promoter methylation. Finally, 10 publications with 422 patients and 219 controls were identified in this meta-analysis. Of these studies, seven studies were performed in Caucasians, [30] [31] [32] [33] [34] [35] [36] while three studies were conducted in Asians. [37] [38] [39] The detection of RASSF1A promoter methylation applied methylation-specific polymerase chain reaction and quantitative methylation-specific polymerase chain reaction. With regard to the type of control sample, normal tissue was used in five studies, 31, 33, 35, 36, 39 four studies applied benign tissue, 31, 32, 35, 38 and adjacent tissue was applied in two studies 34, 37 ( Figure 1 ; Tables 1 and S1-S6) .
Quantitative data synthesis
According to this meta-analysis, there was a significant association of RASSF1A promoter methylation with thyroid Table 2 ). 
literature qualities
In this meta-analysis, 10 studies were scored by NOS table by two independent authors. The scores of eligible literatures ranged from 6 to 8, suggesting that the quality of included studies were of a high quality and the inclusion criteria were satisfied. The detailed information is shown in Table 1 . 
Publication bias and sensitivity analysis
Trial sequential analysis
Trial sequential analysis indicated that Z-curve crossed the traditional boundary and the monitoring boundary for benefit, which indicated that no further studies were performed to study this association of RASSF1A promoter methylation with thyroid cancer risk. The Z-curve did not reach the boundary of RIS, and the RIS was 1,115. In other associations, no trial sequential analysis was conducted for the small number of samples (Figure 8 ). 
Discussion
Epigenetic alternations play an important role in the regulation of gene expression, especially in mammalian cells. DNA methylation usually occurs in CpG islands -clusters of CpGs of gene promoter region, which can lead to gene activation or inactivation. The hypermethylation of gene promoter represses gene expression by inhibiting gene transcription and further affects the total cell signal pathway. The inactivation of RASSF1A, one of tumor suppressor genes, is critical in the tumorigenesis of thyroid cancer. The changes in gene structure, deletion, or mutation can result in the irreversible loss of RASSF1A function. Alternatively, the cumulative RASSF1A methylation can also influence the expression and affect the progression of cancers, such as tumor differentiation and metastasis. In previous studies of Figure 5 Funnel plot of publication biases on the association between ras-associated domain family 1a promoter methylation and thyroid cancer risk.
Funnel plot with pseudo 95% confidence limits
Odds ratio receptor, fibroblast growth factor type 1 existed in thyroid cancers. [42] [43] [44] RASSF1A protein, lacking enzymatic activity, contains a Ras-association domain and can regulate the cell cycle and apoptosis. 13, 14 Many studies have found that the RASSF1A promoter inactivation was frequent in thyroid cancers, 30% of thyroid tumors, 33, 34, 37, 39 but other reports also observed that the RASSF1A promoter methylation did not have significant correlations with thyroid cancer risk. 31, 35, 36 Thus, it is necessary to conduct a meta-analysis to determine the strength of association between RASSF1A promoter methylation and thyroid cancer. In the literature retrieval, a previous meta-analysis was found. 45 However, the meta-analysis only explored the association between RASSF1A promoter methylation and PTC risk, and no clinical information was included. The result of the previous study indicated a significant association of RASSF1A promoter methylation with PTC risk. This was the same result in this meta-analysis. To discuss the association of RASSF1A promoter methylation with FTC risk, distant metastasis, and TNM-stage, the meta-analysis was conducted.
In this study, the results indicated that aberrant methylation of RASSF1A promoter was more frequently detected in thyroid cancer than in noncancerous controls. In the included studies, although the results of Wang et al 39 and Qu et al 37 demonstrated that the frequency of RASSF1A promoter methylation increased the risk of thyroid cancer, the pooled ORs and 95% CI show that there was a significant association thyroid cancers, many genes methylation have a significant association with the development of thyroid tumor. For example, p16INK4A/CDKN2A, p21CIP1/CDKN1B, and p27KIP1/CDKN1B, considering as tumor suppressors, can regulate the activity of cyclin-CDK complexes in mammalian cells. However, the expression of these genes in which promoter methylation is detected in 30% of thyroid tumor was commonly downregulated in thyroid cancer patients. 40, 41 In addition, the hypermethylation of thyrotropin receptor gene, receptor, fibroblast growth factor type 2, and between RASSF1A promoter methylation and the risk of thyroid cancer in Asians. Furthermore, a small degree of heterogeneity among studies was noticed in the overall analysis. Therefore, the stratified analysis, on the basis of sample type and ethnicity, was carried out to reduce the heterogeneity. At the same time, the pooled ORs indicated that the significant association was found in the stratified analysis based on ethnicity and sample type. Furthermore, between-study heterogeneity, to a large extent, disappeared in the subgroup analysis. This phenomenon indicated that the sample type and ethnicity were the primary cause of heterogeneity. Interestingly, no significant association between the frequency of RASSF1A promoter methylation in thyroid malignant tumor and the frequency in thyroid benign tumor existed. In other subgroups, the higher frequency of FTC and PTC group was found, compared with the nontumorous group. From all eligible studies in this meta-analysis, no results indicated that the RASSF1A promoter methylation had a significant influence in the metastasis of thyroid tumor. 30, [36] [37] [38] [39] In the meantime, the result of this statistical analysis was similar to the previous studies (for M0-stage and M1-stage: OR=1.18, 95% CI=0.64-2.16, P0.05). Moreover, no significant association between the frequency of RASSF1A methylation and TNM-stage of thyroid cancer (for I-stage and II-IV-stage: OR=1.79, 95% CI=0.72-4.44, P0.05) was found. In the included studies, one study found a significant association, 38 but two studies obtained negative results. 30, 38 These results were inconsistent, but now, to a large extent, we could say that the frequency of RASSF1A promoter methylation might not be related with the TNM-stage of thyroid cancer. Certainly, the small sample size may limit the power of statistics. From the trial sequential analysis, although no studies were continuously performed to evaluate the association of RASSF1A promoter methylation with thyroid cancer risk, further studies, investigating the association between RASSF1A promoter methylation and thyroid cancer pathogenesis, were still needed to be carried out.
In this meta-analysis, the publication bias was not detected in the eligible studies. Begg's test, Egger's test, and funnel plot were performed, which indicated that the data did not have a considerable discrepancy among studies. Furthermore, consistent results were found in sensitivity analysis. However, several potential limitations must be emphasized in this study. First, with few included studies in this meta-analysis, the influence of small sample size of case and control cannot be ruled out. Second, the value of cut-off point of methylation cannot be achieved, thus the sensitivity and specificity of methylation about thyroid cancer risks cannot be determined. Third, the clinical information was so little that the analysis of association of RASSF1A promoter methylation with the pathogenesis of thyroid cancer patients cannot be performed.
Conclusion
This meta-analysis showed that RASSF1A promoter methylation might play an important role in thyroid cancer initiation and progression. The RASSF1A promoter methylation might be a promising biomarker for the early diagnosis of thyroid cancer. In addition, RASSF1A promoter methylation was associated with the increased risk of distant metastasis and late TNM-stage of thyroid cancer patients. However, in consideration of the limitations acknowledged above, more large-scale, multicenter, and well-designed case-control or cohort researches will provide more insights into the role of RASSF1A promoter methylation in the risk and pathogenesis of thyroid cancer.
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